Product: The CELT ACD®
Vasorum is developing medical devices for the interventional cardiology and radiology markets.It has developed and received CE Mark for Celt ACD® an arterial puncture closure device which affects the closure of a puncture site after percutaneous catheter-based vascular procedures such as angiography, angioplasty or placement of a stent. Celt ACD® achieves closure by applying a biocompatible implant to both the inside and the outside of the puncture site in the femoral artery (which is deep to the skin in the groin area) at the level of the arterial wall. Extensive development work and a successful European clinical trial has been completed which has demonstrated that Celt ACD® 5 French, 6 French and 7 French device sizes provides rapid hemostasis and are safe to use. The company is currently carrying out clinical trials which will lead to FDA-US approval for Celt ACD® in mid-2014.
THIS DEVICE IS NOT FOR SALE IN THE UNITED STATES – IT IS AN INVESTIGATIONAL DEVICE LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE.
Vasorum was founded in November 2005 by James Coleman, Christopher Cummins and Robert Perryman, who have extensive experience in the medical device industry and in particular in the development of vascular closure devices.
Vasorum is developing medical devices for the interventional cardiology and radiology markets. Its first product is the Celt ACD®, used to close arterial puncture holes.